Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Sage rapeutics | Mind Blowing Facts

8 Analysts Have This to Say About Sage Therapeutics

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:

Sage Therapeutics Earnings Perspective: Return On Capital Employed

Sage Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase in earnings, the company posted a loss of $122.06 million.

Analyst Ratings for Sage Therapeutics

Analyst Ratings for Sage Therapeutics

Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Sage Therapeutics: Q1 Earnings Insights

Sage Therapeutics (NASDAQ:SAGE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Sage Therapeutics (NASDAQ:SAGE) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Expert Ratings For Sage Therapeutics

Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

1

Organisations

Advanced Micro Devices

Dell Technologies

Coinbase Global

Canaccord Genuity

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

418,126 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play